ANNEX ISupplementary provisions
ANNEX I Pursuant to paragraph 3 of Decision XII/2 of the 12th Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following Parties have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following products: Product Country Salbutamol Terbutaline Fenoterol Orciprenaline Reproterol Carbuterol Hexoprenaline Pirbuterol Clenbuterol Bitolterol Procaterol Beclomethasone Dexamethasone Fluinisolide Fluiticasone Budesonide Triamcinolone Ipratropium bromide Oxitropium Bromide Austria X X X X X X X X X X X Belgium X X X X X X X X X X X Czech Republic X X X X X X X X X X X Denmark X X X X X X X X X X X Finland X France X Germany X X X X X X X X X X X X X X X X X X X Greece X X X X X X X X X X X Ireland X Luxembourg X Portugal X X X X X X X X X X X The Netherlands X X X X X X X X X X X Norway X X X X X X X X X X X Sweden X UK X Source: www.unep.org/ozone/dec12-2-3.pdf